Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Monsanto Company and Complix NV Sign Collaboration

Published: Friday, September 21, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
Collaboration agreement to develop Complix’s proprietary Alphabody® protein technology in the field of agriculture.

Monsanto Company and Complix NV have announced that they have entered into a collaboration agreement to evaluate and develop Complix’s proprietary Alphabody® protein technology in the field of agriculture.

Complix is a biopharmaceutical company focused on the discovery and development of its Alphabody® technology platform.

Alphabodies are a unique class of protein therapeutics that are potentially active against a broad range of disease targets, including intracellular targets.

Alphabodies are small single chain alpha-helical proteins that are designed by computer modelling, but are inspired by naturally existing protein structures. This collaboration represents the first application of Complix’s Alphabody® technology in agriculture.

“Complix’s expertise in protein targeting technology offers a novel platform to further enhance our trait development capabilities,” said Bob Reiter, Monsanto’s Vice President of Biotechnology.

Reiter continued, “We believe this technology offers great promise and could contribute to development of new traits to protect plants from pests and diseases. We are pleased to work with Complix to develop this promising technology in a way that might deliver on-farm benefits to our grower customers.”

Under the terms of the agreement, Complix will grant Monsanto worldwide exclusive rights to access Complix’s Alphabody® platform technology for use in plant agriculture.

Complix retains the exclusive rights on any discoveries made under this collaboration for use outside the field of plant agriculture.

The agreement also includes options to expand the collaboration across multiple applications within plant agriculture. Further terms were not disclosed.

“We are delighted to have concluded this agreement with Monsanto, a leading agricultural company with a strong track record of delivering innovations to the marketplace,” said Mark Vaeck, Chief Executive Officer of Complix NV.

Vaeck continued, “By working with Monsanto, our partner of choice for this space, I am confident that we will be able to apply our Alphabody platform to address some of the most important challenges facing agriculture today and tomorrow. This strategic alliance, will also enable us to create significant value for our shareholders as it will contribute to further strengthening and expanding our Alphabody platform and help Complix to establish its leadership position in the field of cross-over therapeutics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Monsanto Acquires Select Assets of Agradis, Inc.
Monsanto also signs research collaboration agreement with and makes equity investment in Synthetic Genomics Inc., co-founding company of Agradis, Inc.
Monday, February 04, 2013
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!